Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
Swedish Orphan Biovitrum AB (Sobi) has entered into a definitive agreement to acquire Arthrosi Therapeutics Inc. for $950 million upfront and up to $550 million in milestone payments. The deal brings the investigational gout drug pozdeutinurad (AR882) into Sobi’s pipeline, positioning the oral URAT1 inhibitor as a potential anchor asset in a late-stage inflammatory franchise. […]
Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Wenzhou KanryBio Biotechnology Co., Ltd. have entered into a strategic collaboration focused on co-developing high-value reagents and products for biomarker assay kits. Announced on December 10, 2025, this partnership aims to combine Sanyou Biopharmaceuticals’ global leadership in AI-driven molecular discovery with KanryBio Biotechnology’s capabilities in kit product development and […]
FDA clears Prilenia’s PREVAiLS ALS trial. Can pridopidine validate neuroprotection and shift the treatment paradigm? Read the full analysis here.